GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of [Discussion] the hepatic fat advice in here is 2 years out of date — 6 comments in the full submission. View in context.
0
c/survodutide·submitted 1 year ago by u/thermal_mass_tom

[Discussion] the hepatic fat advice in here is 2 years out of date

Discussionbranch of 6 comments

the hepatic fat advice in here is 2 years out of date. Change my mind, genuinely — I have no stake in being right about this. The relevant figures are 2 years, and they come from the same log I have kept the whole time. Imaging-derived liver fat fraction is a surrogate. It correlates with histology imperfectly, and a…

Read the full submission and all 6 comments →

This branch

6 comments, started 1 year ago
u/farid_kuipers0 points·1 year ago

The escalation schedules in the published protocols are slow and deliberate, and the tolerability tables show why. That is a description of the trials rather than a suggestion for anybody.

replysharereportpermalink
u/cato_girard1 point·1 year ago

The escalation schedules in the published protocols are slow and deliberate, and the tolerability tables show why.

Adding the standing caveat — unapproved compound, research material is not for human use.

replysharereportpermalink
u/ismael_nwosu1 point·1 year ago

That figure is from the obesity programme, and this thread is about the hepatic one.

replysharereportpermalink
u/rafael_sjoberg1 point·1 year ago

the titration in the trials was slow and deliberate

replysharereportpermalink
u/thermal_mass_tomOP1 point·1 year ago·edited

the titration in the trials was slow and deliberate

Disagreeing with this bit: that number comes from a different programme with a different population.

replysharereportpermalink
u/thermal_mass_tomOP-20 points·1 year ago·edited

Are you reading the publication or a summary?

replysharereportpermalink

← back to the whole thread

About c/survodutide

Survodutide-specific discussion: glucagon-receptor co-agonism, the hepatic fat and MASH resolution data, and how the side-effect profile compares with GIP-based dual agonism. Small community, high signal.

12kmembers
62submissions
Feb 2024created
submissions / month, last year
Sponsored

Janoshik Analytical

Independent HPLC and mass spec. The number you get is the number they found.

janoshik.comSponsored

GL Biochem (Shanghai)

Custom peptides and amino acids direct from the manufacturer since 1998. ISO 9001 / cGMP. Batch COA every order.

glbiochem.net
More in c/survodutide
c/survodutide rules
  1. Glucagon co-agonism has a distinct safety story. Do not generalise from tirzepatide.
  2. MASH claims need the trial and the biopsy endpoint.
  3. Not approved. Descriptive posts only.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/incretin_ivyu/liver_enzyme_lizu/trialwatch_theo
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →